Search Result
Results for "
isoniazid
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0329
-
|
INH; Isonicotinic acid hydrazide; Isonicotinic hydrazide
|
Bacterial
Autophagy
Mitophagy
Antibiotic
|
Infection
|
|
Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .
|
-
-
- HY-147263
-
|
CC-11050
|
Phosphodiesterase (PDE)
|
Infection
Inflammation/Immunology
|
|
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .
|
-
-
- HY-B0329S
-
|
INH-d4; Isonicotinic acid hydrazide-d4; Isonicotinic hydrazide-d4
|
Bacterial
Autophagy
Mitophagy
Antibiotic
|
Infection
|
|
Isoniazid-d4 is the deuterium labeled Isoniazid. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .
|
-
-
- HY-B1048
-
|
Paraniazide; Pasiniazide; Isonicotinic acid hydrazide p-aminosalicylate
|
Bacterial
|
Infection
|
|
Pasiniazid is a chemical complex formed by Isoniazid (HY-B0329) and Para-aminosalicylic acid in a 1:1 molar ratio. Pasiniazid is an antibacterial agent. Pasiniazid is rapidly decomposed into isoniazid and para-aminosalicylic acid in the gastrointestinal tract. Isoniazid exerts a bactericidal effect, while para-aminosalicylic acid delays the acetylation process of isoniazid. Pasiniazid has antibacterial activity against Mycobacterium tuberculosis. Pasiniazid can be used in tuberculosis research .
|
-
-
- HY-129043
-
|
|
Drug Metabolite
|
Infection
|
|
3-Formyl rifamycin is an acid degradation product of the broad-spectrum antibiotic Rifampicin (HY-B0272). 3-Formyl rifamycin forms via acid hydrolysis of Rifampicin in an acidic environment .
|
-
-
- HY-101059
-
|
|
GABA Receptor
|
Neurological Disease
|
|
FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a Ki of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions .
|
-
-
- HY-I0736
-
-
-
- HY-B0329R
-
|
INH (Standard); Isonicotinic acid hydrazide (Standard); Isonicotinic hydrazide (Standard)
|
Reference Standards
Bacterial
Autophagy
Mitophagy
Antibiotic
|
Infection
|
|
Isoniazid (Standard) is the analytical standard of Isoniazid. This product is intended for research and analytical applications. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .
|
-
-
- HY-100048
-
|
AcINH
|
Drug Metabolite
|
Infection
|
|
Acetylisoniazid is a primary Isoniazid (HY-B0329) metabolite mediated by N-acetyltransferase (NAT). Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .
|
-
-
- HY-145525
-
|
CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester
|
Endogenous Metabolite
|
Others
|
|
Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.
|
-
-
- HY-P3016B
-
|
EC 2.6.1.1, Human liver; GOT, Human liver; AST, Human liver
|
Aminotransferases (Transaminases)
|
Cardiovascular Disease
|
|
Aspartate aminotransferase (EC 2.6.1.1), Human liver is a metabolic regulator with the highest activity in the heart, liver and skeletal muscle. Aspartate aminotransferase, Human liver comprises two isozymes: the cytoplasmic form (AST1) and the mitochondrial form (AST2). By catalyzing reversible transamination reactions between oxaloacetate, L-glutamate and other substances, it is deeply involved in key physiological processes such as amino acid metabolism, the tricarboxylic acid cycle and neurotransmitter synthesis. Aspartate aminotransferase, Human liver also provides substrate support for the synthesis of urea and purines/pyrimidines. Aspartate aminotransferase, Human liver is a serum marker reflecting cardiac and hepatic injury, and its abnormal levels are also closely associated with myocardial infarction, cardiovascular diseases and various cancers .
|
-
-
- HY-117492
-
|
Isonicophen
|
Bacterial
|
Infection
|
|
Aconiazide (Isonicophen) is a orally active hydrazone derivative of isoniazid, and can be used for study of tuberculosis .
|
-
-
- HY-129943
-
|
|
Bacterial
|
Infection
|
|
Benzothiohydrazide is an analogue of anti–tubercular agent Isoniazid. Benzothiohydrazide exhibits anti–tubercular activity, with MICs of 132 μM and 264 μM for M. tuberculosis wild type (H37Rv) and clinical mutant strains (IC1 and IC2) .
|
-
-
- HY-161542
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-158289
-
-
-
- HY-76293
-
I2906
1 Publications Verification
|
Bacterial
|
Infection
|
|
I2906 is an orally active isocitrate lyase (ICL) inhibitor with a Mycobacterium tuberculosis IC50 of 134.3 μg/mL. I2906 inhibits the growth of Mycobacterium tuberculosis. I2906 can be used for the research of tuberculosis .
|
-
-
- HY-157870
-
|
|
Bacterial
|
Infection
|
|
Mtb-IN-6 (Compound C10) is a Mycobacterium tuberculosis(Mtb) respiration inhibitor. Mtb-IN-6 can enhance the bactericidal activity of isoniazid (INH, HY-B0329). Mtb-IN-6 inhibits WT Mtb with an IC50 of 25 µM .
|
-
-
- HY-101059R
-
|
|
GABA Receptor
Reference Standards
|
Neurological Disease
|
|
FGIN 1-27 (Standard) is the analytical standard of FGIN 1-27. This product is intended for research and analytical applications. FGIN 1-27, an indoleacetamide, is a specific peripheral benzodiazepine receptor (PBR) ligand with a Ki of 5.0 nM. FGIN 1-27 can penetrate the blood brain barrier (BBB). FGIN 1-27 inhibits the onset of Isoniazid-induced convulsions .
|
-
-
- HY-N9934R
-
|
3-DHS (Standard); 5-Dehydroshikimic acid (Standard)
|
Drug Intermediate
Reference Standards
|
Others
|
|
Isonicotinic acid (Standard) is the analytical standard of Isonicotinic acid. This product is intended for research and analytical applications. Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C .
|
-
-
- HY-I0736S
-
-
-
- HY-155722
-
|
|
Bacterial
|
Infection
|
|
Mtb-IN-5 (compound (-)17j) is an isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity. Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .
|
-
-
- HY-I0736R
-
|
|
Reference Standards
Drug Metabolite
Drug Intermediate
|
Infection
|
|
Isonicotinic acid (Standard) is the analytical standard of Isonicotinic acid (HY-I0736). This product is intended for research and analytical applications. Isonicotinic acid is an Isoniazid (HY-B0329) metabolite. The Isonicotinic acid derivative Enisamium inhibits the replication of multiple subtypes of influenza A virus .
|
-
-
- HY-155720
-
|
|
Bacterial
|
Infection
|
|
Mtb-IN-4 (compound 17h) is a nontoxic isoxazole, with anti-Mycobacterium tuberculosis (Mtb) activity (IC50=0.70 μM). Mtb-IN-4 inhibits Mtb respiration and biofilm formation in macrophage, and enhances antibiotic isoniazid (INH) inhibition against INH-resistant Mtb mutant .
|
-
-
- HY-158380
-
|
|
Bacterial
|
Infection
|
|
UH-NIP-16 exhibits antimicrobial activity against Mycobacterium tuberculosis, with MIC50 of 1.86 and 3.05 μM, for pathogenic mycobacterial strains H37Rv and CDC1551. UH-NIP-16 synergizes with Streptomycin (HY-B1906), Isoniazid (HY-B0329), Ethambutol (HY-B0535) and Bedaquiline (HY-14881), potentiates their anti-tuberculosis activities .
|
-
-
- HY-175016
-
|
|
Endogenous Metabolite
|
Infection
Metabolic Disease
|
|
NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb). NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329)) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52) .
|
-
-
- HY-179649
-
|
|
Bacterial
|
Infection
|
|
sALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid (HY-10394) and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis .
|
-
-
- HY-118647
-
|
Etisul
|
Bacterial
|
Infection
|
|
Ditophal is an orally active thiol ester anti-tuberculosis and anti-leprosy agent. Ditophal combats Mycobacterium tuberculosis infections in subcutaneous and intracerebral sites in guinea pigs, including isoniazid (HY-B0329)-resistant strains. Ditophal alters the staining characteristics of Mycobacterium leprae and reduces the bacterial index of leprosy. Ditophal causes ulcers at the injection site when administered subcutaneously to guinea pigs at high doses. Ditophal can be used in the research of tuberculosis and leprosy .
|
-
-
- HY-175987
-
|
|
Bacterial
|
Infection
|
|
Antimycobacterial agent-12 (Compound Ec42), a derivative of Platensimycin (HY-127146), is a dual-functional inhibitor KasA and KasB. Antimycobacterial agent-12 has antibacterial activity with a MICs of 2, 2 and 4 μg/mL against Staphylococcus aureus ATCC 29213, Mycobacterium smegmatis and its Isoniazid (HY-B0329)-resistant strain, respectively. Antimycobacterial agent-12 has a superior antimycobacterial activity in M. smegmatis-infected mouse models. Antimycobacterial agent-12 can be used for tuberculosis research .
|
-
-
- HY-W170126
-
|
|
Bacterial
|
Infection
|
|
CB6513745 is a MelF flavin-dependent oxidoreductase inhibitor with a Ki of 18 μM against Mycobacterium marinum MelF. CB6513745 inhibits the activity of MelF flavin-dependent oxidoreductase via hydrophobic interactions with the binding pocket of the protein. CB6513745 is applicable to research related to tuberculosis .
|
-
-
- HY-165396
-
|
|
Bacterial
|
Infection
|
|
HC103A is an Antibacterial agent and a DosS/DosT histidine sensor kinase inhibitor, with an IC50 of 0.5 μM against DosS and ~5 μM against DosT of *Mycobacterium tuberculosis*. HC103A inhibits the autophosphorylation of DosS/DosT. HC103A suppresses hypoxia-induced triacylglycerol synthesis and the viability of Mtb. HC103A can be used in the research of tuberculosis .
|
-
-
-
HY-L142
-
|
|
151 compounds
|
|
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.
Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.
MCE supplies a unique collection of 151 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development
|
| Cat. No. |
Product Name |
Type |
-
- HY-161542
-
|
|
Biochemical Assay Reagents
|
|
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-158289
-
|
|
Biochemical Assay Reagents
|
|
Isoniazid-KLH is a biochemical reagent that can be used as a biological material or organic compound for life science related research .
|
-
- HY-N9934R
-
|
3-DHS (Standard); 5-Dehydroshikimic acid (Standard)
|
Biochemical Assay Reagents
|
|
Isonicotinic acid (Standard) is the analytical standard of Isonicotinic acid. This product is intended for research and analytical applications. Isonicotinic acid is a metabolite of Isoniazid. Isoniazid is converted to Isonicotinic acid by hydrazinolysis, with the Isoniazid to Isonicotinic acid biotransformation also to be catalyzed by cytochrome P450 (CYP) enzymes, e.g., CYP2C .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0329S
-
|
|
|
Isoniazid-d4 is the deuterium labeled Isoniazid. Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity .
|
-
-
- HY-I0736S
-
|
|
|
Isonicotinic acid-d4 is the deuterium labeled Isonicotinic acid (HY-I0736). Isonicotinic acid is an Isoniazid (HY-B0329) metabolite. The Isonicotinic acid derivative Enisamium inhibits the replication of multiple subtypes of influenza A virus .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
